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The Complement System in Bullous Pemphigoid: VII. Fixation of the 
Regulatory Protein /JlH Globulin by Pemphigoid Antibody 
CHANG w. LEE, M.D., AND ROBERT E. JORDON, M.D. 
Fro m the Cutaneous Immunopathology Unit, R esearch. Service, 1-\food Veterans Administration Medical Center, Milwaukee, Wisconsin; the 
Dermatology Section, Department of Medicine, The Medical College of Wisconsin, Milwaukee, Wisconsin., U.S.A. 
Using in vitro complement immunofluorescent stain-
ing methods, serum samples from 5 active cases of bul-
lous pemphigoid, with pemphigoid antibody titers of 320 
or greater, were tested for their ability to fix the regu-
latory protein {JlH globulin in addition to C4 and C3. All 
5 samples yielded positive C3, C4 and {JlH staining re-
actions in a linear fashion along the basement membrane 
zone. Heat inactivation or treatment of the complement 
source (fresh normal human serum) with EDTA, Mg2-
EGTA abolished all 3 staining reactions. Substitution of 
C2-deficient serum as the source of complement in-
hibited both C3 and {JlH staining but had no effect on C4 
staining. Use of serum devoid of {JlH (R{JlH) minimally 
enhanced C3 staining while no {JlH staining was ob-
served. The addition of {JlH to R{JlH restored positive 
,81H staining. Skin biopsies of perilesional skin from 6 
patients with b u llous pemphigoid demonstrated heavy 
in vivo deposition of {JlH in addition to C3. These studies 
suggest that pemphigoid antibodies will fix the regula-
tory protein {JlH in addition to other complement com-
ponents, a phenomenon which requires activation of the 
classical complement pathway and generation of the C3b 
amplification convertase. 
The complement system is comprised of at least 19 distinct 
serum proteins, which, when activated, generate a number of 
biologically active substances which are important mediators of 
inflammation [1]. This system of proteins has been implicated 
in the pathogenesis of bullous pemphigoid, a subepidermal 
blistering skin disease characterized immunologically by the 
presence of autoantibody to skin and mucosal basement mem-
brane zone (BMZ), as demonstrated by indirect immunofluo-
rescence (IF) staining [2,3]. 
By direct IF staining, BMZ deposition of C3 is seen in 
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Abbreviations: 
BMZ: basement membrane zone 
EACA: e-amino-n-caproic acid 
EDT A: ethylenediamine-tetraacetate 
EGTA: ethylene glycol-his (B-aminoethyl ether)-N,N,N', N',-tet-
raacetic acid 
IEP: immunoelectrophoresis 
IF: immunofluorescence 
NHS: normal human serum 
RP: normal human serum devoid of properdin 
SDS: sodium dodecyl sulfate 
virtually all bullous pemphigoid skin lesions, even in the appar-
ent absence of lgG [ 4-6]. Other complement· components in-
cluding classical pathway components (Clq and C4) and alter-
native pathway components (factor B [B] and properdin [P]) , 
are similarly deposited in skin lesions along the BMZ [7,8]. 
Using in vitro complement IF methods, bullous pemphigoid 
antibodies are avid complement fixers and will flx both classical 
(Clq and C4) and alternative (Band P) pathway components in 
addition to C3 [9-11]. Fixation of B and P occw-s via the 
amplification convertase (C3b dependent C3 convertase) of the 
alternative pathway following generation of C3b by classical 
pathway activation, a phenomenon which explains the presence 
of B and P in bullous pemphigoid skin lesions [ll]. 
Recently, Carlo et a! [12] demonstrated by. IF the presence 
of {JlH globulin bound to the BMZ in bullous pemphigoid skin 
lesions. {J1H globulin is a cofactor for the control protein, the 
C3b inactivator (C3biNA), which inactivates C3b [13,14]. Like 
P and B , {JlH globulin also binds to C3b, which explains its 
presence in skin lesions. Oul' investigations therefore were de-
signed to determine if: (1) bullous pemphigoid antibodies will 
fix {J1H globulin in vitro, and (2) fixation of {J1H globulin, as 
with fixation of B and P , is due to binding to the C3b amplifi-
cation convertase of the alternative pathway following classical 
pathway activation. 
R eagents 
Reagents used in these studies included: DEAE-Sephacel, 
Sepharose 4B, L-lysine coupled Sepharose 4B, Sepharose 6B 
(Pharmacia Fine Chemicals, Uppsala, Sweden); agarose, poly-
ethylene glycol (PEG) 6000, ethylene glycol-his (B-aminoethyl 
ether)-N 1N 1N\ N\ -tetraacetic acid (EGTA) (Sigma Chemical 
Co., St. Louis, MO); ethylenediamine-tetraacetate (EDTA) 
(Fisher Scientific Co., PittsbUl'gh, P A) and hydroxylapatite 
(Galiard-Schlesinger Chemical, Long Island, NY). 
Specimens 
Five sera from active bullous pemphigoid patients, with anti-
BMZ antibody titers of 320 or greater by indirect IF staining, 
were utilized in the in vitro complement IF studies. These 
serum samples were stored at -20°C, while fresh normal human 
serum (NHS), C2-deficient serum and serum devoid of ,BlH 
globulin (R{J1H), used as sow-ces of complement, were stored 
at - 70°C until used. To insure that the alternative pathway 
was intact, the C2-deficient serum was tested by immunoelec-
trophoresis (IEP) with and without the addition of inulin. Using 
monospecific antisera to both C3 and B, C3 and B conversion 
were noted after the addition of inulin. By hemolytic assays, 
C2-deflcient serum hemolytic complement (CH50) and hemo-
lytic C2 were unmeasUTable. Hemolytic Cl, C4 and C3, however, 
were intact. · 
Purification of C3 and ,81 H Globulin 
C3 and ,BlH were purified from normal human plasma using 
a modification of the procedUl'e of Tack and Prahl [15]. In this 
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method, human plasma is fractionated with PEG-4000, and the 
5-10% PEG fraction is depleted of plasminogen by passage over 
a column of L-lysine coupled Sepharose 4B. The eluent is then 
applied to a DEAE-Sephacel column using a linear salt gra-
dient, and the second peak, containing ,BlH globulin and the 
third peak, containing primarily C3, were eluted at a specific 
conductance of 4.7 and 6.5 M ho/cm at 4 °C, respectively. These 
2 peaks were concentrated and applied separately to a Sepha-
rose 6B column (5 X 100 em) equilibrated with 0.1 M KP04 
buffer pH 7.4 containing 0.15 M NaCl, 0.005 M EDTA and 0.05 
M EACA. When the ,81H globulin containing peak was chro-
matographed on Sepharose 6B, ,81H globulin eluted in the large 
protein peak (Fig 1) just prior to C3. This ,81H column had a 
flow rate of 12 ml/hr, and 4-ml fractions were collected. The 
ascending part of the peak containing ,81H was pooled (48 ml) 
and had a protein concentration of 1.1 mg P /ml. This ,81H peak 
was then rechromatographed on Sepharose 6B to remove any 
remaining C3 and other contaminants. 
The DEAE-Sephacel C3 containing peak was also chro-
matographed on Sepharose 6B (flow rate 21 ml/hr; 7-ml frac-
tions collected) followed by purification using hydroxylapatite 
column chromatography. By the Ouchterlony analysis, both 
the purified ,81H globulin and C3 contained minimal lgA con-
tamination. This was removed using affinity chromatography 
with anti-IgA coupled to Sepharose 4B. Monospecific antiserum 
to IgA was the gift of Dr. Nickolas J. Calvanico (Wood Veterans 
Administration Medical Center, Milwaukee, WI). The purity of 
both proteins was then confirmed by double immunodiffusion 
(Ouchterlony), IEP and polyacrylamide disc gel electrophoresis 
(Fig 2). Monospecific antiserum to ,81H globulin, used to test 
our ,81H preparation, was kindly supplied by Dr. Shaun Ruddy 
(The Medical College of Virginia, Richmond, VA). 
Antisera 
Antisera to human ,81H globulin and human C3 were pre-
pared by methods previously outlined in detail [16]. Labeled 
goat antiserum of human lgG (Meloy Laboratories, Inc., Spring-
field, VA), rabbit antiserum to human C4 (Behring Diagnostics, 
Inc., Hoechst Pharmaceuticals, Sommerville, NJ), and goat 
anti-rabbit lgG (Hyland Division, Travenol Laboratories, Costa 
Mesa, CA) were purchased. Prior to use, all antisera were 
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FIG 1. Sepharose 6B gel chromatography of the DEAE-Sephacel 
,BlH containing peak. Protein content is shown (solid line) with ,BlH 
eluting in the large protein peak. Contaminating C3 (broken line) was 
detected tailing the /11H containing peak. The ,BlH containing fractions 
(large peak) were rechromatographed on Sepharose 6B to remove 
contaminating C3. 
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FIG 2. Disc gel electrophoresis of purified ,BlH and C3. ,BlH (a) and 
C3 (b) were electrophoresed in 1.0 X 10 em 5% polyacrylamide gel. 
Both proteins exhibited single bands of similru· molecular weight. Under 
reducing conditions with 10% polyacrylamide gel with 1% SDS, C3 (c) 
appears dissociated into oo and B chains; ,BlH was not dissociated. 
checked for specificity and activity by both double immunodif-
fusion and IEP. Characteristics of om various labeled antisera, 
including unitage, antibody-protein assays, fluorescein-protein 
ratios, and use dilutions conformed to our previously published 
standards [16]. 
Immunodiffusion and IEP 
Double immunodiffusion was carried out in 1% agarose in 
glycine EDTA buffer at neutral pH. Plates were developed at 
room temperatme and read in 24 hr. 
IEP was run in 2% agarose in veronal buffer at pH 8.0, ionic 
strength 0.05, containing 0.01 M EDTA for 1-1/2 hr on 50 volt, 
15 milliamperage. Slides were developed at room temperatme 
and read in 24 hr. 
Polyacrylamide disc gel electrophoresis was performed ac-
cording to the method of Davis [17] in 5% polyacrylamide gel 
at pH 9.5. Gels were run in duplicate with approximately 100 
p.g of ,81H and 80 p.g of C3; one of the gels was fixed with 12.5% 
trichloroacetic acid and stained with Coomassie blue (Fig 2). 
Fmther analysis of C3 was carried out on sodium dodecyl 
sulfate (SDS) 10% polyacrylamide gel electrophoresis after 
reduction in 1% SDS with 0.1 M dithiothreitol as described by 
Weber, Osborn and Pringle [18]. 
IF Procedures 
Indirect IF (IgG) staining was petformed as previously de-
scribed [16] and used to detect BMZ reactive antibodies in 
bullous pemphigoid sera. Only those sera with titers of 320 or 
greater were tested fmther. 
In vitro C3 staining was carried out using a 2-step method 
described previously [10,11]. Normal human skin sections were 
treated with heat inactivated (56°C for 30 min) serum dilutions 
(1:10, 1:20, 1:40, etc) . These were prepared with fresh NHS 
diluted 1:10 in veronal buffered saline containing 0.5 mM mag-
nesium chloride and 0.15 mM of calcium chloride (VBs++). This 
resulted in a complement concentration of approximately 10-
15 hemolytic units/mi. In vitro ,81H and C4 staining were 
performed using a 3-step procedme outlined in our previous 
studies [10,11]. In step 1, the normal human skin sections were 
treated with heat inactivated (56°C for 30 min) patient serum 
dilution plus human complement. In step 2, the tissues were 
treated with unlabeled rabbit anti-human ,81H or anti-human 
Dec.l980 
C4. The final step involved treating the sections with labeled 
goat anti-rabbit IgG. 
Routine controls as well as experimental controls for in vitro 
complement IF staining were performed as previously described 
[9-11], and are included in Table I. Selective specificity controls 
and controls designed to determine the mode of complement 
activation and interaction of ,81H with C3 were also included. 
These consisted of heat inactivation of the complement somce, 
addition of Mg-EGTA (0.5 mM Mg++, 15 mM EGTA), in addi-
tion to EDTA (10 mM). Additional controls were the substitu-
tion of C2-deficient serum and R,81H (serum devoid of ,81H 
globulin) as the complement somces. To confirm the specificity 
of both C3 and ,81H staining reactions, both the antiserum to 
C3 and the antiserum to ,81H were absorbed with highly pmi-
fied C3 and ,81H. 
Direct and modified indirect IF, used to detect C3 and ,81H 
in skin lesions, was performed by the methods previously out-
lined in detail [7,8]. 
Preparation of R,BlH 
To make serum devoid of ,81H, fresh normal serum containing 
0 .01 M EDTA was applied on the affinity absorbent Sepharose 
4B column containing monospecific antibody to ,BlH. The 
R,B1H portion of the serum was free of any trace amount of 
/31H by immunodiffusion and IEP. It was dialyzed against 
normal saline to be free of EDT A and once more dialyzed 
against normal saline containing 0.5 mM of magnesium and 0.15 
mM of calcium prior to use. 
By hemolytic complement assay, the CH5o of R,BlH was 
higher (75 units) than control serum (50 units) treated in a 
sinlllar fashion, i.e., EDTA addition, simple Sepharose 4B gel 
filtration and dialysis at the same temperatme, dmation and 
buffer concentrations. Before using as a complement somce, 
R,BlH was diluted to the same complement concentration as 
the control serum used as the complement source. 
RESULTS 
The 5 bullous pemphigoid sera yieided positive in vitro C3 
staining (Fig 3a) using the 2-step method; they were also 
positive for ,BlH (Fig 3b), and C4 staining by the 3-step method. 
As in previous studies [9-11], all routine controls for both the 
2-step method (C3 staining) and the 3-step method (,BlH and 
C4 staining) yielded negative results. In addition to indirect IF 
staining, all 5 serum samples were titered by in vitro C3, C4 
and ,BlH staining (Table II). Consistent with om previous 
observations [10,11], none of the pemphigoid sera tested had in 
vitro complement staining titers higher than the indirect IF 
(IgG) titers. ,BlH staining titers were comparable to B and P 
TABLE I. In vitro C3, C4 and fJJH staining reactions with bullous 
p e mphigoid sera. Studies demonstrating mode of fi_-.:ation of C3, C4 
and [JJH 
Absorption Reaction 
S erum Complement treatment/' of antise· 
rum C3 ,BIH C4 
1:2 C. +++ ++ ++ 
1.2" c. +++ ++ ++ 
1.2" C. 56°C for 30 min 
1.2'' C. plus EDTA 
1.2" C. plus Mgz-EGTA 
1.2" C2-deficient serum ++ 
1.2" R{JlW ++++ ++ 
1.2'' R/31H plus /31H +++ ++ ++ 
1.2" C. ,BlH +++ NT 
1.2" c. C3 ++ NT 
" Complement source (fresh normal human serum, C2-deficient se-
rum or R,BlH). 
b 56°C for 30 min. 
c Fresh normal human serum devoid of ,BlH. 
NT = not tested 
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FIG 3. In vitro complement immunofluorescence (lF) staining of the 
basement membrane zone (BMZ) of normal human skin with bullous 
pemphigoid serum. (a) In vitro C3 staining (reduced from x250) ; (b) 
in vitro ,BlH staining (reduced from X250) ; (c ) substitution of C2-
deficient serum for normal human serum as the complement source has 
inhibited positive ,BlH staining (reduced from X250). 
staining titers obtained in a previous study [11], and were lower 
than C3 and C4 staining titers. 
To determine the mode of fixation of ,BlH (in addition to C3 
and C4) by pemphigoid antibodies (i.e., via either the classical 
or alternative pathway), selected control tests were performed 
(Table I) . As expected, heat inactivation of the complement 
source, as well as the addition of EDTA and Mg2-EGTA, 
inhibited ,BlH staining in addition to C3 and C4 staining. When 
C2-deficient serum was used as the source of complement, 
complete inhibition of both C3 and ,BlH staining (Fig 3c) was 
observed, but C4 staining was not affected. These studies there-
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fore suggest that like fixation of C3, B and P [11], fixation of 
,BlH by pemphigoid antibodies is due to activation of comple-
ment via the classical pathway. 
When R,BlH was substituted as the complement source, the 
intensity of the C3 staining was moderately increased when 
compared to the NHS control, while ,B1H staining was absent. 
Reconstitution of R,B1H with ,B1H restored the ,81H staining 
while C3 staining remained about the same. C4 staining was 
not affected by either of these manipulations. 
Absorption of0.1 ml of anti-,B1H and anti-C3 antiserums with 
purified ,B1H (0.1 mg) resulted in complete blocking of the ,B1H 
staining but did not affect C3 staining. Similar absorption of 
both antisera with purified C3 (0.1 mg) blocked the C3 staining 
but not the ,81H staining. 
Skin biopsies of perilesional skin from 6 patients with bullous 
pemphigoid were tested by modified indirect IF for in vivo 
bound ,B1H in addition to the direct IF demonstration of BMZ 
bound C3. All6 skin biopsies demonstrated heavy C3 deposition 
along the BMZ. All 6 of these specimens also demonstrated 
similar deposition of ,B1H (Fig 4). 
DISCUSSION 
With complement activation, either via the classical or alter-
native pathway, C3 is cleaved into a minor fragment, C3a, and 
a major fragment C3b. Such cleavage is accomplished by the 
classical C3 convertase (C42 ), the initial C3 convertase of the 
alternative pathway and the amplification convertases (either 
C3bBb or C3bBbP) which assemble following formation of C3b 
Titers 
Case 
lgG C3 C4 ,BlH 
1 640 80 80 40 
2 320 40 20 20 
3 1280 80 40 20 
4 1280 160 80 40 
5 640 80 80 20 
FIG 4. IF staining of perilesional skin from a bullous pemphigoid 
patient demonstrating deposition of fllH along the BMZ (reduced from 
X500). 
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[1]. P has been shown to bind to a site on the C3b molecule, 
stabilize, and thus prolong the activity of the amplification 
convertase (C3bBb) [19,20]. 
Activation of the C3b amplification mechanism is also influ-
enced by control proteins, including C3b INA and its regulatory 
cofactor ,B1H globulin. First described as a contaminant of both 
C3 and C5 preparations [21], the role of ,B1H has only recently 
been appreciated [14,22,23]. Like P, ,B1H binds physically to 
C3b, but exerts an opposite effect on C3bBb convertase function 
by displacing Bb and allowing C3b to be inactivated by the C3b 
INA to C3i, eventually leading to the formation of 2 inactive 
fragments, C3c and C3d. Since ,81H shares a common binding 
site with B on the C3b molecule, it inhibits the generation of 
amplification convertases, C3bBb or C3bBbP competitively 
[23]. This mechanism then shuts off any fUl"ther activation of 
C3. 
In previous studies, we have shown that bullous pemphigoid 
antibodies will fix Clq, C4, B and P in addition to C3 [9-11]. 
Such studies provided an explanation for the presence of these 
proteins bound in vivo in bullous pemphigoid skin lesions [7,8] 
and for the low levels of these and other complement compo-
nents and the presence of C5-related chemotactic activity in 
bullous pemphigoid blister fluids [24,25]. In addition, ow· pre-
vious in vitro complement IF studies suggested that BMZ 
antibodies activate complement via the classical pathway with 
subsequent generation of the amplification convertase, a phe-
nomenon which explains the fixation of both B and P [ll] and 
the presence of these factors in bullous pemphigoid skin lesions 
[7,8]. 
Recently, Carlo et al [12] reported the presence of ,B1H bound 
to the BMZ in bullous pemphigoid skin lesions. In addition, 
using 2 pemphigoid sera, they have also shown that BMZ 
antibodies will fix ,BlH in vitro in addition to C3. We have now 
confirmed both of these observations and have further dem-
onstrated that, like B and P, ,81H binding by bullous pemphi-
goid antibodies requires activation of the classical pathway. 
With the addition of Mg2-EGTA to the complement source or 
substitution of C2-deficient serum as the souTce of complement, 
inhibition of both C3 and ,BlH staining occwTed. Since, in both 
situations, the classical complement pathway is blocked, while 
the alternative pathway remains intact, fixation of ,81H requires 
an intact classical pathway for C3b generation (amplification 
convertase generation). As expected, the use of C2-deficient 
serum as the complement sow·ce did not inhibit binding of C4 
by bullous pemphigoid antibodies. 
Substitution of R,81H for NHS as the soUl"ce of complement 
minimally increased C3 staining intensity while inhibiting ,BlH 
staining. This is not surprising as in the absence of ,B1H more 
B will bind to C3b, resulting in the production of more ampli-
fication convertase cleaving more native C3. The addition of 
,81H to R,B1H restored ,81H staining, while the intensity of C3 
staining was comparable to that observed when NHS is used as 
the complement soUl"ce. In previous studies [11], the use of 
serum devoid of properdin (RP) as the sow·ce of complement 
resulted in greatly diminished C3 staining. In the absence of P, 
which also binds to C3b, the amplification convertase is rapidly 
broken down by C3b INA and ,BlH [19-21,23]. The interplay of 
both P and ,BlH therefore affects the amount of C3 deposited 
by buUous pemphigoid antibodies. 
The authors are grateful to Dr. Nickolas J . Calvanico for performing 
the polyacrylamide gel electrophoresis studies. We also wish to thank 
Laura Stirling and Catherine Walther for their typing and editorial 
assistance. 
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